BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
LOADING
|||
EV to Sales: Discounted Valuation
Below historical average, structural decline.
Left:
||||
Enterprise value to sales ratio
Latest
5.08
↓ 76% below average
Average (9y)
20.77
Historical baseline
Range
High:70.37
Low:5.08
CAGR
-11.8%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | 5.08 | -9.7% |
| 2023 | 5.63 | -40.7% |
| 2022 | 9.49 | -41.9% |
| 2021 | 16.35 | -76.8% |
| 2020 | 70.37 | +830.6% |
| 2019 | 7.56 | -82.0% |
| 2018 | 42.02 | +152.5% |
| 2017 | 16.64 | -12.0% |
| 2016 | 18.90 | +20.7% |
| 2015 | 15.66 | - |